蛋白质指纹图谱在胃癌新辅助化疗疗效评价中的应用

Evaluation on the application of serum protein fingerprint in neoadjuvant chemotherapy for gastric cancer

【目的】探讨蛋白质指纹图谱与胃癌新辅助化疗疗效的关系。【方法】采用SELDI-TOF蛋白质芯片技术,检测胃癌化疗前血清蛋白指纹图谱,通过比较分析发现差异蛋白质,进一步筛选与新辅助化疗疗效相关的血清蛋白质指纹图谱差异。【结果】17 162、22 331、29 901M/Z蛋白质在无效组中均高表达(P<0.01),有效组和健康组比较无统计学意义。【结论】17 162、22 331、29 901M/Z3种蛋白质有可能成为筛选胃癌新辅助化疗疗效的蛋白分子。血清蛋白质指纹图谱对筛选胃癌新辅助化疗疗效预测分子有潜在应用前景。

【Objective】To investigate the relationship between serum protein fingerprint and neoadjuvant chemotherapy of gastric.【Methods】Using SELDI-TOF protein chip technology detect the serum protein fingerprint before chemotherapy,founding differences by compare and analysis the protein,and further screening the differences that serum protein fingerprint relate to neoadjuvant chemotherapy.【Results】17 162,22 331,29 901 M/Z proteins were highly expressed in the ineffective group（P 0.01）,and there was no statistically significant in effective group and healthy group.【conclusion】The protein of 17 162,22 331 and 29 901 M/Z may become a new effective molecular that screen adjuvant chemotherapy in patients with gastric cancer.The serum protein fingerprint may have potential application for screening the neoadjuvant chemotherapy in patients with gastric cancer.